Drug Profile
IQP 0410
Alternative Names: IQP-0410; SJ-3366Latest Information Update: 28 Jul 2020
Price :
$50
*
At a glance
- Originator Samjin Pharmaceutical Company
- Developer ImQuest Life Sciences
- Class Antiretrovirals; Pyrimidinones; Small molecules
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 20 Jul 2020 ImQuest Life Sciences has been acquired by Cytocom
- 04 Nov 2017 No recent reports of development identified for preclinical development in HIV-infections(First-line therapy) in USA (PO)
- 11 Feb 2009 Antimicrobial data from a preclinical trial in HIV infections presented at the 16th Conference on Retroviruses and Opportunistic Infections (CROI-2009)